Scarica l'app Stockscreener
0.00
100.00%
-8.16
Dopo l'orario di chiusura:
8.02
8.02
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.16
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$564.26M
Reddito:
-
Utile/perdita netta:
$-30.04M
Rapporto P/E:
0.00
EPS:
-1.58
Flusso di cassa netto:
$-27.38M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$8.345
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Nome
Regulus Therapeutics Inc
Settore
Industria
Telefono
858-202-6300
Indirizzo
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Confronta RGLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
0.00 | 564.26M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-03-18 | Iniziato | Leerink Partners | Outperform |
| 2018-03-28 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Iniziato | Leerink Partners | Outperform |
| 2017-06-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-06 | Reiterato | Wedbush | Outperform |
| 2017-01-30 | Downgrade | Needham | Buy → Hold |
| 2017-01-30 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-11-02 | Reiterato | Needham | Buy |
| 2016-07-25 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | FBR Capital | Outperform |
| 2016-06-28 | Reiterato | Needham | Buy |
| 2016-06-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-04-13 | Iniziato | Chardan Capital Markets | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2015-04-21 | Ripresa | FBR Capital | Outperform |
| 2014-11-24 | Iniziato | Deutsche Bank | Buy |
| 2014-08-07 | Reiterato | FBR Capital | Outperform |
| 2013-08-14 | Reiterato | Needham | Buy |
Mostra tutto
Regulus Therapeutics Inc Borsa (RGLS) Ultime notizie
What institutional investors are buying Regulus Therapeutics Inc. stockInvest smarter with actionable trading signals - jammulinksnews.com
What are analysts’ price targets for Regulus Therapeutics Inc. in the next 12 monthsHigh-yield capital appreciation - jammulinksnews.com
What is the dividend policy of Regulus Therapeutics Inc. stockMaximize returns with strategic portfolio planning - jammulinksnews.com
Why is Regulus Therapeutics Inc. stock attracting strong analyst attentionJaw-dropping returns - jammulinksnews.com
How does Regulus Therapeutics Inc. compare to its industry peersBuild a portfolio that delivers consistent profits - jammulinksnews.com
Is it the right time to buy Regulus Therapeutics Inc. stockBuild a diversified portfolio for steady growth - jammulinksnews.com
What drives Regulus Therapeutics Inc. stock priceInvest smarter with daily trading signals - jammulinksnews.com
What are Regulus Therapeutics Inc. company’s key revenue driversConsistently profitable trades - jammulinksnews.com
How volatile is Regulus Therapeutics Inc. stock compared to the marketGet professional advice for portfolio optimization - jammulinksnews.com
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
What catalysts could drive Regulus Therapeutics Inc. stock higher in 2025Real Time Watchlist With Proven Results - jammulinksnews.com
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
What are the technical indicators suggesting about Regulus Therapeutics Inc.Value Investing Picks For Every Investor - jammulinksnews.com
How strong is Regulus Therapeutics Inc. company’s balance sheetAI Powered Picks For Fast Growth - jammulinksnews.com
Is Regulus Therapeutics Inc. stock entering bullish territoryPattern Detection for Entry Confirmation Enabled - metal.it
Will Regulus Therapeutics Inc. stock split in the near futureChart Driven High Reward Trading Setup Presented - metal.it
Reversal Traders Monitor Regulus Therapeutics Inc. for EntryShort Term Buy Zone Stock Alerts Signal Entry - beatles.ru
What are the latest earnings results for Regulus Therapeutics Inc.Superior stock selection - jammulinksnews.com
What is Regulus Therapeutics Inc. company’s growth strategyAchieve breakthrough profits with smart strategies - jammulinksnews.com
Does Regulus Therapeutics Inc. stock perform well during market downturnsConsistent wealth multiplication - jammulinksnews.com
When is Regulus Therapeutics Inc. stock expected to show significant growthUnlock daily market insights for better trades - jammulinksnews.com
What analysts say about Regulus Therapeutics Inc. stockFree Market Volatility Navigation Tips - PrintWeekIndia
Is Regulus Therapeutics Inc. a good long term investmentTriple-digit growth rates - PrintWeekIndia
Regulus Therapeutics Inc. Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
Regulus Therapeutics Inc Azioni (RGLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):